SRP-1003

N/A

Report date: 2025/11/25 10:47:08
NME

Base Information

Drug NameSRP-1003
Drug Alias NameARO-DM1SRP-1003
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionRNA interferenceMyotonin-protein kinase inhibitors
TargetsMyotonin-protein kinase
Therapy Area/IndicationsMyotonic Dystrophy
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryTaiwanThailandNew Zealand +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesArrowhead Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesSarepta Therapeutics IncArrowhead Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsMyotonic Dystrophy
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A